These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. WT1: what has the last decade told us? Little M; Holmes G; Walsh P Bioessays; 1999 Mar; 21(3):191-202. PubMed ID: 10333728 [TBL] [Abstract][Full Text] [Related]
6. Atypical presentation of Denys-Drash syndrome in a female with a novel Wt1 gene mutation. Machin GA Birth Defects Orig Artic Ser; 1996; 30(1):269-86. PubMed ID: 9125334 [No Abstract] [Full Text] [Related]
8. The role of Wilms' tumor genes. Hirose M J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307 [TBL] [Abstract][Full Text] [Related]
9. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features. Mrowka C; Schedl A J Am Soc Nephrol; 2000 Nov; 11 Suppl 16():S106-15. PubMed ID: 11065340 [TBL] [Abstract][Full Text] [Related]
10. Transcriptional regulation by the Wilms' tumour suppressor protein WT1. Wagner KJ; Roberts SG Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928 [TBL] [Abstract][Full Text] [Related]
11. EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Scharnhorst V; Menke AL; Attema J; Haneveld JK; Riteco N; van Steenbrugge GJ; van der Eb AJ; Jochemsen AG Oncogene; 2000 Feb; 19(6):791-800. PubMed ID: 10698497 [TBL] [Abstract][Full Text] [Related]
12. Analysis of native WT1 protein from frozen human kidney and Wilms' tumors. Iben S; Royer-Pokora B Oncogene; 1999 Apr; 18(15):2533-6. PubMed ID: 10229205 [TBL] [Abstract][Full Text] [Related]
13. Expression of the Wilms' tumor suppressor gene, WT1, reduces the tumorigenicity of the leukemic cell line M1 in C.B-17 scid/scid mice. Smith SI; Down M; Boyd AW; Li CL Cancer Res; 2000 Feb; 60(4):808-14. PubMed ID: 10706085 [TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology. Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575 [TBL] [Abstract][Full Text] [Related]
15. Wilms' tumour: connecting tumorigenesis and organ development in the kidney. Rivera MN; Haber DA Nat Rev Cancer; 2005 Sep; 5(9):699-712. PubMed ID: 16110318 [TBL] [Abstract][Full Text] [Related]
16. WT1 splicing alterations in Wilms' tumors. Baudry D; Hamelin M; Cabanis MO; Fournet JC; Tournade MF; Sarnacki S; Junien C; Jeanpierre C Clin Cancer Res; 2000 Oct; 6(10):3957-65. PubMed ID: 11051244 [TBL] [Abstract][Full Text] [Related]
18. Upregulation of c-MYC in WT1-mutant tumors: assessment of WT1 putative transcriptional targets using cDNA microarray expression profiling of genetically defined Wilms' tumors. Udtha M; Lee SJ; Alam R; Coombes K; Huff V Oncogene; 2003 Jun; 22(24):3821-6. PubMed ID: 12802290 [TBL] [Abstract][Full Text] [Related]
19. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study. Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024 [TBL] [Abstract][Full Text] [Related]
20. Evidence for susceptibility genes to familial Wilms tumour in addition to WT1, FWT1 and FWT2. Rapley EA; Barfoot R; Bonaïti-Pellié C; Chompret A; Foulkes W; Perusinghe N; Reeve A; Royer-Pokora B; Schumacher V; Shelling A; Skeen J; de Tourreil S; Weirich A; Pritchard-Jones K; Stratton MR; Rahman N Br J Cancer; 2000 Jul; 83(2):177-83. PubMed ID: 10901367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]